Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward [Pediatric Oncology]
Conclusion
The EFS was uniformly poor for children with recurrent/refractory osteosarcoma in these single-arm phase II trials. We have now constructed baseline EFS outcomes that can be used as a comparison for future phase II trials for recurrent osteosarcoma.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Lagmay, Krailo, Dang, Kim, Hawkins, Beaty, Widemann, Zwerdling, Bomgaars, Langevin, Grier, Weigel, Blaney, Gorlick, Janeway Tags: Osteosarcoma Pediatric Oncology Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Chemotherapy | Children | History of Medicine | Learning | Osteosarcoma | Pediatrics | Radiography | Study | Universities & Medical Training